AdAlta Completes Global Patent Protection for Anti-Fibrotic Drug AD-214 with Canadian Approval
核心洞察
AdAlta Ltd (搜索) has secured a Canadian patent for its lead anti-fibrotic drug candidate AD-214, completing composition-of-matter protection across all major commercial markets including the US, EU, and Japan.
The patent covers the i-body® sequence underpinning AD-214 and extends protection until January 8, 2036, with potential extension to 2043 through additional dosing and treatment method applications.
AD-214 targets idiopathic pulmonary fibrosis (搜索) and kidney fibrosis (搜索), with the company now positioned to advance partnering discussions following positive early-stage clinical and preclinical results.
AdAlta Ltd (搜索) has achieved a significant milestone in protecting its lead anti-fibrotic drug candidate AD-214, securing a Canadian patent that completes composition-of-matter protection across all major commercial markets. The patent, granted by the Canadian Intellectual Property Office, covers the i-body® sequence underpinning AD-214 and carries an expiry date of January 8, 2036.
Comprehensive Global IP Protection Established
With the Canadian patent approval, AD-214 now enjoys robust intellectual property protection in the United States, Canada, European Union, and Japan, as well as in key manufacturing jurisdictions including China and India. This comprehensive coverage represents a critical achievement for the biotechnology company as it positions itself for potential partnering discussions.
The patent encompasses not only the core i-body® sequence but also related pharmaceutical compositions and therapeutic uses, specifically targeting idiopathic pulmonary fibrosis (搜索) (IPF) and kidney fibrosis (搜索)—the primary indications in AD-214's development program.
"Composition of matter patents are the strongest form of patent protection and a key part of the data package partners expect from us," said AdAlta CEO Tim Oldham. "This Canadian patent completes the protection of AD-214 in all major commercial markets and its potential supply chain."
Extended Exclusivity Potential
Beyond the current patent protection, AdAlta has strategically filed additional patent applications covering dosing and treatment methods. If granted, these supplementary patents could extend exclusivity for AD-214 out to 2043, providing nearly two decades of market protection from the current date.
This extended timeline represents substantial commercial value, particularly given the significant development costs and lengthy regulatory pathways typical of anti-fibrotic therapeutics.
Clinical Progress and Partnership Strategy
The company has reported positive early-stage clinical and preclinical results for AD-214, positioning the drug candidate for advancement into later-stage development. AdAlta is actively seeking a commercial partner to support this progression, with the completed global patent portfolio serving as a key asset in partnership negotiations.
The comprehensive intellectual property protection addresses a fundamental requirement for pharmaceutical partnerships, providing potential collaborators with confidence in the drug's commercial exclusivity across major markets.
Broader Pipeline Development
While AD-214 represents AdAlta's lead program in fibrosis, the company maintains a diversified approach through its AdCella (搜索) subsidiary, which is progressing cellular immunotherapy assets targeting solid tumors (搜索) and other high-need disease areas. This multi-pronged strategy positions AdAlta across several therapeutic areas with significant unmet medical needs.